Revolution Medicines (1RVMD) Stock Overview
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1RVMD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$133.10 |
| 52 Week High | US$159.45 |
| 52 Week Low | US$46.20 |
| Beta | 1.41 |
| 1 Month Change | 6.18% |
| 3 Month Change | 58.45% |
| 1 Year Change | 349.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 303.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RVMD | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 1.3% | 0.04% | 3.4% |
| 1Y | 349.7% | 30.7% | 25.1% |
Return vs Industry: 1RVMD exceeded the Italian Biotechs industry which returned 28.1% over the past year.
Return vs Market: 1RVMD exceeded the Italian Market which returned 21.4% over the past year.
Price Volatility
| 1RVMD volatility | |
|---|---|
| 1RVMD Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in IT Market | 8.5% |
| 10% least volatile stocks in IT Market | 3.0% |
Stable Share Price: 1RVMD's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1RVMD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 883 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
Revolution Medicines, Inc. Fundamentals Summary
| 1RVMD fundamental statistics | |
|---|---|
| Market cap | €27.42b |
| Earnings (TTM) | -€1.19b |
| Revenue (TTM) | n/a |
Is 1RVMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RVMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.13b |
| Gross Profit | -US$1.13b |
| Other Expenses | US$246.15m |
| Earnings | -US$1.37b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.7% |
How did 1RVMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 21:47 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revolution Medicines, Inc. is covered by 33 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Walch | Bernstein |
| Alec Stranahan | BofA Global Research |
| Cory Kasimov | Evercore ISI |